ArticleBiotechnology notes (Amsterdam, Netherlands)2022
Synthetic biology in Europe: current community landscape and future perspectives.
Article in Biotechnology notes (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Engineering a Novel Probiotic Toolkit inACS synthetic biology · 2024Article
- Public biofoundries as innovation intermediaries: the integration of translation, sustainability, and responsibility.The Journal of technology transfer · 2024Article
- An integrated engineering worldview of synthetic biology education through the lens of webinar based pedagogy.Frontiers in bioengineering and biotechnology · 2024Article
- Engineered microbial consortia for next-generation feedstocks.Biotechnology notes (Amsterdam, Netherlands) · 2024Article
- Synthetic biology in Indonesia: Potential and projection in a country with mega biodiversity.Biotechnology notes (Amsterdam, Netherlands) · 2023Review
- Building the SynBio community in the Czech Republic from the bottom up: You get what you give.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic biology has captivated scientists' imagination. It promises answers to some of the grand challenges society is facing: worsening climate crisis, insufficient food supplies for ever growing populations, and many persisting infectious and genetic diseases. While many challenges remain unaddressed, after almost two decades since its inception a number of products created by engineered biology are starting to reach the public. European scientists and entrepreneurs have been participating in delivering on the promises of synthetic biology. Associations like the European Synthetic Biology Society (EUSynBioS) play a key role in disseminating advances in the field, connecting like-minded people and promoting scientific development. In this perspective article, we review the current landscape of the synthetic biology community in Europe, discussing the state of related academic research and industry. We also discuss how EUSynBioS has helped to build bridges between professionals across the continent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.